A pipeline of EDEN-designed therapeutics
EDEN designs across therapeutic modalities. Today, it powers three platforms spanning gene insertion, gene editing and protein design. Our therapeutics development team is based in Boston.
Therapeutic platforms
EDEN designs recombinases (LSRs) that can insert long, complex DNA payloads at safe, predictable and well defined genomic sites, without double stranded breaks. These small proteins can easily be delivered in vivo via LNPs and/or AAVs.
We design novel gene editing systems that enable a wide range of edits, from simple gene knockout to targeted, high fidelity insertion of large, complex DNA.
EDEN designs and optimises proteins and peptides across disease areas, combining low sequence identity to marketed molecules with defined developability metrics and demonstrated efficacy in animal models.
Therapeutic pipeline
Therapeutic pipeline
Lead optimisation
PROGRAM
Cell Therapy
Oncology
Indication
Hematological malignancies
Discovery
PROGRAM
Cell Therapy
Oncology
Indication
Solid Tumour
Lead optimisation
PROGRAM
Cell Therapy
Autoimmunity
Indication
Not disclosed
Lead optimisation
PROGRAM
Gene Therapy
Liver
Indication
PKU
Lead optimisation
PROGRAM
Peptides
Various
Indication
AMR
Discovery
PROGRAM
Peptides
Diabetes
Indication
Various
Partner with us,
from asset to platform
Take a single EDEN-designed candidate forward into your own pipeline, co-develop around a target or indication, or access EDEN's full design capability across modalities in a multi-program collaboration.
Get in touch
